Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100
Debt
Debt-to-Equity Ratio0.65
Current Ratio27.80
Quick Ratio26.44
Price-To-Earnings
Trailing P/E Ratio-18.15
Forward P/E Ratio-15.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.18 million
Price / Sales275.71
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book9.98
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-64,020,000.00
Net Margins-1,568.29%
Return on Equity-51.23%
Return on Assets-44.59%
Miscellaneous
EmployeesN/A
Outstanding Shares53,980,000
Market Cap$1,130.94
Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions
What is Accelerate Diagnostics' stock symbol?
Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."
How were Accelerate Diagnostics' earnings last quarter?
Accelerate Diagnostics Inc (NASDAQ:AXDX) posted its quarterly earnings results on Wednesday, May, 9th. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.05. The medical research company had revenue of $0.80 million for the quarter, compared to analysts' expectations of $2.64 million. Accelerate Diagnostics had a negative net margin of 1,568.29% and a negative return on equity of 51.23%. View Accelerate Diagnostics' Earnings History.
What price target have analysts set for AXDX?
2 Wall Street analysts have issued 12 month target prices for Accelerate Diagnostics' stock. Their predictions range from $25.00 to $25.00. On average, they expect Accelerate Diagnostics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 17.1% from the stock's current price. View Analyst Ratings for Accelerate Diagnostics.
What is the consensus analysts' recommendation for Accelerate Diagnostics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Accelerate Diagnostics stock?
Here are some recent quotes from research analysts about Accelerate Diagnostics stock:
- 1. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (7/10/2018)
- 2. BTIG Research analysts commented, "Outlook Remains The Same As the company preannounced Q4 revenue and provided FY18 revenue expectations on January 10th , the company’s formal earnings call was fairly straightforward without surprises. The messaging was largely consistent with what we learned from the company’s JPM conference presentation though we now may expect an update on progress with the FDA on the LRTI test as early as the Q1 call. Overall, we remain very positive on the technology and the total opportunity but feel the company needs to consistently hit estimates through the course of the year for the Street to regain comfort with the model. We maintain our Neutral rating. Modestly tweaking our estimates for gross margin. Our revenue estimates are unchanged but we have increased our gross margin estimates to reflect better trends in Q4. Our full year FY18 revenue estimate is $25M and we assume roughly 2/3 of revenue will be recognized in the 2H. For Q1, we model a slight uptick sequentially from Q4 revenue of $2.12M to $3.2M; of note, this estimate also seems to be lower than other estimates on the Street of $4-5M. Given the timing of hospital purchasing, we prefer to have a conservative bias in the start of the year. Valuation: Shares are Neutral rated based on our DCF analysis. Risks follow." (2/18/2018)
Who are some of Accelerate Diagnostics' key competitors?
Some companies that are related to Accelerate Diagnostics include Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).
Who are Accelerate Diagnostics' key executives?
Accelerate Diagnostics' management team includes the folowing people:
- Mr. Lawrence Mehren, Pres, CEO & Director (Age 52)
- Mr. Steve Reichling, Chief Financial Officer (Age 40)
- Mr. Joan Martin, Exec. VP & Head of Europe, Middle East and Africa (Age 49)
- Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 54)
- Mr. Kurt Reinhardt, Head of Operations
Has Accelerate Diagnostics been receiving favorable news coverage?
Media headlines about AXDX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Accelerate Diagnostics earned a news sentiment score of 0.16 on Accern's scale. They also gave press coverage about the medical research company an impact score of 43.72 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Accelerate Diagnostics' major shareholders?
Accelerate Diagnostics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Thompson Investment Management Inc. (0.06%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, Lawrence Mehren, Matthew Strobeck and Steven Reichling. View Institutional Ownership Trends for Accelerate Diagnostics.
Which institutional investors are buying Accelerate Diagnostics stock?
AXDX stock was bought by a variety of institutional investors in the last quarter, including Thompson Investment Management Inc.. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler and Matthew Strobeck. View Insider Buying and Selling for Accelerate Diagnostics.
How do I buy shares of Accelerate Diagnostics?
Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accelerate Diagnostics' stock price today?
One share of AXDX stock can currently be purchased for approximately $21.35.
How big of a company is Accelerate Diagnostics?
Accelerate Diagnostics has a market capitalization of $1.13 billion and generates $4.18 million in revenue each year. The medical research company earns $-64,020,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.
How can I contact Accelerate Diagnostics?
Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]
MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
